2017
Ovarian reserve testing: a user’s guide
Tal R, Seifer DB. Ovarian reserve testing: a user’s guide. American Journal Of Obstetrics And Gynecology 2017, 217: 129-140. PMID: 28235465, DOI: 10.1016/j.ajog.2017.02.027.Peer-Reviewed Original ResearchConceptsOvarian reserve testingOvarian reserve testsOvarian reserveAntimüllerian hormoneDay 3 follicle-stimulating hormonePolycystic ovary syndromeFemale cancer patientsFollicle-stimulating hormoneFertility treatment optionsSelection of treatmentAntral follicular countAge-specific valuesGood predictive valueComplex clinical phenomenonOvarian hyperstimulationOvarian stimulationOvary syndromeGonadotoxic therapyTreatment optionsCancer patientsPoor responseReproductive ageFollicular countReproductive endocrinologistsTreatment protocol
2013
Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation
Tal R, Seifer DB, Grazi RV, Malter HE. Angiopoietin-1 and angiopoietin-2 are altered in polycystic ovarian syndrome (PCOS) during controlled ovarian stimulation. Vascular Cell 2013, 5: 18. PMID: 24156373, PMCID: PMC3895756, DOI: 10.1186/2045-824x-5-18.Peer-Reviewed Original ResearchPolycystic ovarian syndromeAng-2 levelsAng-1 levelsPCOS womenNumber of oocytesAng-2Ovarian stimulationRetrieval dayAngiopoietin-2Follicular fluidAng-1Angiopoietin-1Serum Ang-1 levelsSerum Ang-2 levelsAng-1/AngSerum Ang-1Prospective cohort studyOvarian hyperstimulationOvarian syndromeCohort studyOvarian functionCapillary leakageFF levelsDay 3Time pointsTransforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation
Tal R, Seifer DB, Shohat-Tal A, Grazi RV, Malter HE. Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation. Fertility And Sterility 2013, 100: 538-543. PMID: 23684116, DOI: 10.1016/j.fertnstert.2013.04.022.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntigens, CDCase-Control StudiesEndoglinFemaleFertilization in VitroFollicular FluidHumansInfertility, FemaleOvarian Hyperstimulation SyndromeOvulation InductionPolycystic Ovary SyndromeReceptors, Cell SurfaceSperm Injections, IntracytoplasmicTransforming Growth Factor beta1UltrasonographyYoung AdultConceptsPolycystic ovarian syndromeSerum soluble endoglinDay of hCGSoluble endoglinFollicular fluidTGF-β1Oocyte retrievalOvarian stimulationHCG administrationControl womenDay 3Pathogenesis of PCOSNon-PCOS control groupProspective case-control studyNon-PCOS controlsSerum TGF-β1Non-PCOS womenPolycystic ovary syndromeTGF-β1 levelsReproductive technology unitCase-control studyGrowth factor-β1Day of retrievalOvarian hyperstimulationOvarian syndromeWhy we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone
Toner JP, Seifer DB. Why we may abandon basal follicle-stimulating hormone testing: a sea change in determining ovarian reserve using antimüllerian hormone. Fertility And Sterility 2013, 99: 1825-1830. PMID: 23548941, DOI: 10.1016/j.fertnstert.2013.03.001.Peer-Reviewed Original Research
2011
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve
Buyuk E, Seifer DB, Illions E, Grazi RV, Lieman H. Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve. Fertility And Sterility 2011, 95: 2364-2368. PMID: 21529798, DOI: 10.1016/j.fertnstert.2011.03.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersBody Mass IndexCross-Sectional StudiesDown-RegulationFemaleFollicle Stimulating Hormone, HumanHumansInfertility, FemaleLinear ModelsNew YorkOocyte RetrievalOverweightOvulationOvulation InductionReproductive Techniques, AssistedRisk AssessmentRisk FactorsConceptsElevated body mass indexNormal ovarian reserveBody mass indexSerum AMH levelsOvarian reserveNumber of oocytesAMH levelsObese womenInfertile womenMass indexHormone levelsDay 3 serum FSH levelsSerum anti-Mullerian hormone (AMH) levelsAnti-Mullerian hormone levelsLow serum AMH levelsSerum antimullerian hormone (AMH) levelsNormal body mass indexAntimullerian hormone levelsReproductive technology cyclesSerum FSH levelsDiminished ovarian reserveIU/L.Cross-sectional studyOvarian hyperstimulationIVF cycles
2007
Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance
Seifer DB, MacLaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertility And Sterility 2007, 88: 539-546. PMID: 17559842, DOI: 10.1016/j.fertnstert.2007.02.014.Peer-Reviewed Original ResearchConceptsPolycystic ovarian diseaseMullerian Inhibiting SubstanceOvarian reserveOvulation inductionInhibiting SubstanceDiagnosis of PCODRisk of OHSSOvarian growth factorsWidespread clinical useOvarian hyperstimulationOvarian diseaseOvarian functionMEDLINE reviewClinical significanceIntracycle variabilityEarly markerClinical useConventional markersDiagnostic markerGrowth factorSpecific cutIntercycle variabilityDifferent assaysMarkersDiagnosis
1992
Baseline ovarian cysts do not affect clinical response to controlled ovarian hyperstimulation for in vitro fertilization**Presented at the 47th Annual Meeting of The American Fertility Society, Orlando, Florida, October 21 to 24, 1991.
Penzias A, Jones E, Seifer D, Grifo J, Thatcher S, DeCherney A. Baseline ovarian cysts do not affect clinical response to controlled ovarian hyperstimulation for in vitro fertilization**Presented at the 47th Annual Meeting of The American Fertility Society, Orlando, Florida, October 21 to 24, 1991. Fertility And Sterility 1992, 57: 1017-1021. PMID: 1572468, DOI: 10.1016/s0015-0282(16)55019-5.Peer-Reviewed Original ResearchConceptsBaseline ovarian cystsNumber of folliclesOvarian cystsOvarian hyperstimulationIVF cyclesClinical responseStimulation regimenBaseline E2 levelBaseline serum estradiolCycle cancellation ratePeak serum E2Vitro Fertilization ProgramAmerican Fertility SocietyNumber of oocytesSerum E2Serum estradiolNumber of cystsCycle outcomeE2 levelsCyst sizeFertility SocietySuch cystsCancellation rateYale University SchoolOwn control
1991
Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success**Presented in part at the Society for Gynecologic Investigation, San Antonio, Texas, March 20 to 23, 1991.
Seifer D, Thornton K, DeCherney A, Lavy G. Early pituitary desensitization and ovarian suppression with leuprolide acetate is associated with in vitro fertilization-embryo transfer success**Presented in part at the Society for Gynecologic Investigation, San Antonio, Texas, March 20 to 23, 1991. Fertility And Sterility 1991, 56: 500-504. PMID: 1909977, DOI: 10.1016/s0015-0282(16)54548-8.Peer-Reviewed Original ResearchConceptsLeuprolide acetatePituitary desensitizationOvarian suppressionPregnancy ratePg/Group IOvarian hyperstimulationIVF-ETE2 responseGroup IIHuman menopausal gonadotropinControlled ovarian hyperstimulationFertilization-embryo transferSerum estradiol levelsNumber of oocytesHuman chorionic gonadotropinHigher pregnancy ratePg/mLMenopausal gonadotropinIVF patientsRetrospective seriesEstradiol levelsGynecologic InvestigationInfertility practiceMenstrual cycle